IT1229517B - Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative. - Google Patents

Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.

Info

Publication number
IT1229517B
IT1229517B IT8919261A IT1926189A IT1229517B IT 1229517 B IT1229517 B IT 1229517B IT 8919261 A IT8919261 A IT 8919261A IT 1926189 A IT1926189 A IT 1926189A IT 1229517 B IT1229517 B IT 1229517B
Authority
IT
Italy
Prior art keywords
acid
disorders
treatment
preparation
pharmaceutically acceptable
Prior art date
Application number
IT8919261A
Other languages
English (en)
Italian (it)
Other versions
IT8919261A0 (it
Inventor
Cristina Le Grazie
Original Assignee
Bioresearch Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioresearch Spa filed Critical Bioresearch Spa
Publication of IT8919261A0 publication Critical patent/IT8919261A0/it
Priority to IT8919261A priority Critical patent/IT1229517B/it
Priority to AT90101570T priority patent/ATE88895T1/de
Priority to DE9090101570T priority patent/DE69001493T2/de
Priority to DK90101570.1T priority patent/DK0382019T3/da
Priority to ES90101570T priority patent/ES2055175T3/es
Priority to EP90101570A priority patent/EP0382019B1/en
Priority to JP2019369A priority patent/JPH0757727B2/ja
Application granted granted Critical
Publication of IT1229517B publication Critical patent/IT1229517B/it
Priority to GR920403210T priority patent/GR3007790T3/el
Priority to US08/386,188 priority patent/US5538734A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IT8919261A 1989-01-31 1989-01-31 Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative. IT1229517B (it)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IT8919261A IT1229517B (it) 1989-01-31 1989-01-31 Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.
ES90101570T ES2055175T3 (es) 1989-01-31 1990-01-26 Utilizacion del acido 5-metiltetrahidrofolico, del acido 5-formiltetrahidrofolico y de sus sales farmaceuticamente aceptables, para la preparacion de composiciones farmaceuticas de liberacion retardada adecuadas para la utilizacion en la terapia de trastornos depresivos, y las co
DE9090101570T DE69001493T2 (de) 1989-01-31 1990-01-26 Verwendung von 5-methyltetrahydrofolsaeure, 5-formyltetrahydrofolsaeure sowie deren pharmazeutisch geeigneten salzen zur herstellung von arzneimitteln mit gesteuerter freigabe zur verwendung in der therapie depressiver stoerungen sowie die auf diese weise hergestellten arzneimittel.
DK90101570.1T DK0382019T3 (da) 1989-01-31 1990-01-26 Anvendelse af 5-methyltetrahydrofolsyre, af 5-formyltetrahydrofolsyre og af deres farmaceutisk acceptable salte til fremstilling af farmaceutiske præparater med reguleret frigivelse egnet til anvendelse ved terapi af depressive forstyrrelser, og således fremstillede farmaceutiske præparater
AT90101570T ATE88895T1 (de) 1989-01-31 1990-01-26 Verwendung von 5-methyltetrahydrofolsaeure, 5formyltetrahydrofolsaeure sowie deren pharmazeutisch geeigneten salzen zur herstellung von arzneimitteln mit gesteuerter freigabe zur verwendung in der therapie depressiver stoerungen sowie die auf diese weise hergestellten arzneimittel.
EP90101570A EP0382019B1 (en) 1989-01-31 1990-01-26 Use of 5-methyltetrahydrofolic acid, of 5-formyl-tetrahydrofolic acid and of their pharmaceutically acceptable salts for the preparation of controlled release pharmaceutical compositions suitable for the use in the therapy of depressive disturbances, and pharmaceutical compositions thus prepared
JP2019369A JPH0757727B2 (ja) 1989-01-31 1990-01-31 抑うつ障害の治療用に適した制御放出製薬組成物
GR920403210T GR3007790T3 (OSRAM) 1989-01-31 1993-05-06
US08/386,188 US5538734A (en) 1989-01-31 1995-02-09 5-methyltetrahydrofolic acid, 5-formyl-tetrahydrofolic acid and their pharmaceutically acceptable salts for use in the therapy of depressive disturbances

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT8919261A IT1229517B (it) 1989-01-31 1989-01-31 Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.

Publications (2)

Publication Number Publication Date
IT8919261A0 IT8919261A0 (it) 1989-01-31
IT1229517B true IT1229517B (it) 1991-09-03

Family

ID=11156204

Family Applications (1)

Application Number Title Priority Date Filing Date
IT8919261A IT1229517B (it) 1989-01-31 1989-01-31 Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.

Country Status (9)

Country Link
US (1) US5538734A (OSRAM)
EP (1) EP0382019B1 (OSRAM)
JP (1) JPH0757727B2 (OSRAM)
AT (1) ATE88895T1 (OSRAM)
DE (1) DE69001493T2 (OSRAM)
DK (1) DK0382019T3 (OSRAM)
ES (1) ES2055175T3 (OSRAM)
GR (1) GR3007790T3 (OSRAM)
IT (1) IT1229517B (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
CN1122456C (zh) 1996-01-31 2003-10-01 南亚拉巴马医学科学基金会 含有天然的还原叶酸盐异构体的食品和维生素制品
GB2336534A (en) * 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
ES2292238T3 (es) * 1998-04-24 2008-03-01 Scarista Limited Tratamiento de la depresion y preparaciones farmaceuticas para el mismo.
AU5547099A (en) * 1998-08-03 2000-02-28 Epigenesis Pharmaceuticals, Inc. A new analgesic, anti-inflammatory and wound healing agent
JP2002527484A (ja) * 1998-10-19 2002-08-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング セントジョーンズワートならびにジヒドロおよびテトラヒドロ葉酸の誘導体を含有する、うつ病の治療および予防のための天然製剤
DE69906345T2 (de) * 1998-10-30 2004-02-12 Merck Patent Gmbh Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten
CH693905A5 (de) * 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
US20020094970A1 (en) * 2000-12-14 2002-07-18 Ronenn Roubenoff Compositions and methods for treating an arthritic condition
WO2002085297A2 (en) * 2001-04-24 2002-10-31 East Carolina University Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease
WO2002085296A2 (en) * 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
AU2003269889B2 (en) * 2002-06-17 2007-04-19 Epigenesis Pharmaceuticals, Llc Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
US7405207B2 (en) * 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20110209699A1 (en) * 2003-07-31 2011-09-01 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050085430A1 (en) * 2003-07-31 2005-04-21 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) * 2003-07-31 2009-12-03 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026880A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
US20050043282A1 (en) * 2003-07-31 2005-02-24 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090285899A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026848A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20090274676A1 (en) * 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
NZ598171A (en) 2009-07-10 2014-11-28 Linzy O Scott Iii Methods and compositions for treating thyroid-related medical conditions with reduced folates
AU2011215669B2 (en) * 2010-02-12 2015-06-04 HedoniaUSA, Inc. Compositions and methods for treating depression
AU2017397463B2 (en) 2016-11-03 2022-01-06 HedoniaUSA, Inc. Compositions and methods for treating depression
CA3058287A1 (en) 2017-03-31 2018-10-04 Merck Patent Gmbh Crystalline sodium salt of 5-methyl-(6s)-tetrahydrofolic acid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1572137A (en) * 1977-02-22 1980-07-23 Bioresearch Sas Del Dr Livio C Stable compositions for therapeutic use based on d,1-5-methyltetrahydrofolic acid and its salts
GB2072504B (en) * 1980-03-27 1983-10-26 Coppen A J Pharmaceutical compositions
US4550109A (en) * 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8621268D0 (en) * 1986-09-03 1986-10-08 Univ Strathclyde Separation of substances
IT1204612B (it) * 1987-05-14 1989-03-10 Bioresearch Spa Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.

Also Published As

Publication number Publication date
DK0382019T3 (da) 1993-06-07
EP0382019B1 (en) 1993-05-05
ATE88895T1 (de) 1993-05-15
GR3007790T3 (OSRAM) 1993-08-31
ES2055175T3 (es) 1994-08-16
EP0382019A1 (en) 1990-08-16
IT8919261A0 (it) 1989-01-31
US5538734A (en) 1996-07-23
JPH02240021A (ja) 1990-09-25
JPH0757727B2 (ja) 1995-06-21
DE69001493D1 (de) 1993-06-09
DE69001493T2 (de) 1993-08-26

Similar Documents

Publication Publication Date Title
GR3007790T3 (OSRAM)
IT1229203B (it) Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PT1235826E (pt) Acrilamidas de quinuclidina
AU4732989A (en) Pyrimidines and their pharmaceutical acceptable salts thereof, and their use as medicines
NZ227680A (en) Quinoline and naphthyridine derivatives, intermediates and pharmaceutical compositions
FI862011A0 (fi) Terapeutiska nukleosider.
SI1427708T1 (sl) Derivati amino-ftalazinona kot zaviralci kinaze, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
UA34416C2 (uk) Похідні хроману, активні стосовно 5-нт рецептора, спосіб їх одержання та проміжні сполуки
ES2084579T3 (es) Uso de buspirona en la preparacion de una composicion farmaceutica para el tratamiento del abuso del alcohol.
PT83080A (en) Process for the preparation of biciclic naphthyridine compounds or analogs and their salts soluates hydrates and esters
MX10059A (es) Procedimiento para la preparacion de antagonistas de leucotrienos novedosos y producto obtenido
DE69005860D1 (de) Verwendung von 5'-Deoxy-5'-methylthioadenosin S-adenosylmethionin und dessen Salzen zur Herstellung von Seborrhea vermindernden Arzneimitteln.
GB9310095D0 (en) Therapeutic compounds
HUP0002963A3 (en) Use of pyrazolo-[4,3-d] pyrimidinon derivatives for the production of pharmaceutical compositions for treating diseases of the eye field
MY108482A (en) Compounds.
GB9109972D0 (en) Therapeutic compounds
ES555118A0 (es) Metodo de preparar medicamentos que incluyen un agente buscador de hueso y un inhibidor de anhidrasa carbonica, para impedir y curar enfermedades oseas.
BR0112619A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, métodos para o tratamento de distúrbios mediados por 5-hidroxitriptamina, e de distúrbios no sistema nervoso central e/ou de bexiga hiperativa ou vasospasmo ou para o controle do crescimento de tumores
ES537205A0 (es) Procedimiento para preparar derivados de purina
IL111580A (en) Use of melatonin derivatives in the preparation of pharmaceutical compositions for use in treating sleep disorders
IL90959A0 (en) Guanine derivatives,their preparation and pharmaceutical compositions containing them
NZ228182A (en) Substituted 4,5,6,7-tetrahydroisothiazolo(4,5-c) pyridine derivatives and pharmaceutical compositions; methods for preparation
IT1232352B (it) Derivati dell'acido chinurenico ad attivita' sul sistema nervoso centrale, loro preparazione e relative composizioni farmaceutiche
GR3033394T3 (en) New alkaloid derivatives, their use and pharmaceutical formulations containing them.
IT8321031A0 (it) Loro derivati, aventi attivita'sali di calcio di amminoacidi o di terapeutica, procedimento per laloro preparazione e composizioni farmaceutiche che li contengono.

Legal Events

Date Code Title Description
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19940203